H pylori eradication therapy for prevention of gastric cancer

  • Ford AC & al.
  • Gut
  • 23 Mar 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Helicobacter pylori (H pylori) eradication therapy reduces the incidence of gastric cancer and cancer-related mortality in both healthy individuals and patients with gastric neoplasia in East-Asian countries.

Why this matters

  • Findings support screening for, and treatment of, H. pylori in healthy individuals and in patients with gastric neoplasia, as a means of reducing the future incidence of gastric cancer.

Study design

  • 7 randomised controlled trials including 8323 healthy individuals and 3 trials including 1841 patients with gastric neoplasia met eligibility criteria.
  • Funding: None.

Key results

  • In healthy individuals, eradication therapy reduced the incidence of gastric cancer (risk ratio [RR], 0.54; 95% CI, 0.40-0.72) and cancer-related mortality; and but did not affect all-cause mortality (RR, 0.61; 95% CI, 0.40-0.92).
  • In patients with gastric neoplasia, eradication therapy reduced the incidence of future gastric cancer (RR, 0.49; 95% CI, 0.34-0.70).
  • Adverse events were incompletely reported by the majority of trials.

Limitations

  • Only one trial was conducted outside East Asia.